Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances.
Ito T, Igarashi H, Jensen RT.
Best Pract Res Clin Gastroenterol. 2012 Dec;26(6):737-53. doi: 10.1016/j.bpg.2012.12.003.
Neuroendocrine neoplasia and bone (Review).
Ghemigian A, Carsote M, Sandru F, Petca RC, Oproiu AM, Petca A, Valea A.
Exp Ther Med. 2021 Nov;22(5):1219. doi: 10.3892/etm.2021.10653. Epub 2021 Aug 26.
Tumors of the endocrine pancreas.
Friesen SR.
N Engl J Med. 1982 Mar 11;306(10):580-90. doi: 10.1056/NEJM198203113061005.
"Somatostatinoma": follow-up studies.
Ganda OP, Soeldner JS.
N Engl J Med. 1977 Dec 15;297(24):1352-3. doi: 10.1056/NEJM197712152972417.
Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs).
Kanakis G, Kaltsas G.
Best Pract Res Clin Gastroenterol. 2012 Dec;26(6):791-802. doi: 10.1016/j.bpg.2012.12.006.
Management of functional neuroendocrine tumors of the pancreas.
Öberg K.
Gland Surg. 2018 Feb;7(1):20-27. doi: 10.21037/gs.2017.10.08.
Somatostatinoma syndrome. Biochemical, morphologic and clinical features.
Krejs GJ, Orci L, Conlon JM, Ravazzola M, Davis GR, Raskin P, Collins SM, McCarthy DM, Baetens D, Rubenstein A, Aldor TA, Unger RH.
N Engl J Med. 1979 Aug 9;301(6):285-92. doi: 10.1056/NEJM197908093010601.
Pancreatic somatostatinoma. Clinical features and physiological implications.
Larsson LI, Hirsch MA, Holst JJ, Ingemansson S, Kühl C, Jensen SL, Lundqvist G, Rehfeld JF, Schwartz TW.
Lancet. 1977 Mar 26;1(8013):666-8. doi: 10.1016/s0140-6736(77)92113-4.
Update on the diagnosis and treatment of rare neuroendocrine tumors.
Friesen SR.
Surg Clin North Am. 1987 Apr;67(2):379-93. doi: 10.1016/s0039-6109(16)44190-3.
[Diagnostics and treatment in functional pancreatic neuroendocrine tumours].
Müssig K, Dudziak K, Horger M, Anlauf M, Goretzki PE.
Dtsch Med Wochenschr. 2011 Jun;136(24):1319-30. doi: 10.1055/s-0031-1280554. Epub 2011 Jun 7.
